Search results
Is Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?
Investor's Business Daily· 5 days agovaccine in partnership with Merck. The shot prompts an immune response against a patient's own tumor...
ESCMID 2024: Highlights on prophylaxis and treatment of infectious diseases
Clinical Trials Arena via Yahoo Finance· 6 days agoAdditionally, there were no cases of HPV6/11/16/18/31/33/45/52/58-related high-grade intraepithelial...
First cancer jab trial finds they 'weaponise immunse system to attack tumours'
The US Sun· 6 days agoA NEW mRNA cancer vaccine can reprogram the immune system to attack tumours within 48 hours, a study shows. The first-ever human clinical trial of four adult patients showed ...
CDC Found Evidence COVID-19 Vaccines Caused Deaths
WSAU Wausau· 6 days agoIn an exclusive report by the Epoch Times, U.S. Centers for Disease Control and Prevention (CDC) officials fou...
3 No-Brainer Stocks to Buy in May
Motley Fool via Yahoo Finance· 2 days ago*Stock Advisor returns as of April 30, 2024 David Jagielski has no position in any of the stocks mentioned. Keith Speights has positions in Pfizer and...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 4 hours agoValneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates Q1 financial highlights Total revenues of €32.8 million, including sales of €32.1 million, on track to meet anticipated full year guidance
Study identifies immunity threshold for protection against COVID-19 in children
Medical Xpress· 7 days agoUniversity Hospital (NUH). All participants received two doses of 10mcg Pfizer/BioNTech mRNA COVID-19 vaccination, 21 days apart. The team followed up with the participants ...
Arbutus Biopharma Corp Reports Q1 2024 Earnings: A Detailed Financial Review
GuruFocus.com via Yahoo Finance· 5 days agoLitigation and ...continues to defend its intellectual property vigorously, particularly in ongoing litigation with Moderna and Pfizer/BioNTech over lipid nanoparticle technology ...
Arbutus Biopharma Corp Reports Q1 2024 Earnings: A Detailed Fina
Guru Focus· 5 days agoRevenue: Reported at $1.5 million for Q1 2024, a significant decrease from $6.7 million in Q1 2023, falling short of the estimated $2.15 million.Net Loss: Reco
Big Pharma Has Captured Osteoporosis
Mercola· 4 days agoThe sales funnel concept is crucial to understanding the modern medical industry. The second funnel involves framing preventative medicine as screening individuals for potential health risks ...
